Momenta Pharmaceuticals, Inc. (MNTA)

[Regulardoc]

I am not approaching this from MNTA's side, but from WPI's side. Agree with Dew that there is NVS to be considered, but if WPI's internal evaluation of its legal exposure suggests a significant legal and dollar exposure, this is one way to address it. I do not currently own WPI but have traded it the last 2 months and have owned MNTA for many years and agree that it is worth more than $22/share (yet it clearly is nowhere near that now). If the market softens, $22/share will look quite attractive to many investors.

Again, simply an option for Watson for reasons listed in original post. Also would widen their biosimilar portfolio beyond AMGN relationship.